Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Gilead Sciences, Inc. GILD

Healthcare  —  Drug Manufacturers General
150.93 1.24 0.83% as of 25 Sep
Market cap
$183.2B
P/E
0.0×
S&P 500 Member Dividend Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Gilead Sciences, Inc. (GILD) EV/EBITDA

As of 25 September 2026, Gilead Sciences, Inc. (GILD) trades at a EV/EBITDA of 804×. Over the past ten years it has ranged from 5.4× (December 2016) to 812× (September 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 13.3× (55.34%)
FY2024 29.8× 149.58%
FY2023 11.9× (11.50%)
FY2022 13.5× 43.63%
FY2021 9.4× (47.06%)
FY2020 17.7× 20.47%
FY2019 14.7× 78.38%
FY2018 8.3× 20.61%
FY2017 6.8× 12.05%
FY2016 6.1× (8.82%)

Quarterly

Period EV/EBITDA Change
Jun 2026 687× 4,708.00%
Mar 2026 14.3× 7.51%
Dec 2025 13.3× 13.33%
Sep 2025 11.7× (19.51%)
42 more quarters

Against its own ten years

Low 5.4× High 812×
Ten-year median 10.6×
Current reading's percentile 100

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
PFE Pfizer Inc. compare 10.5×
BMY Bristol Myers Squibb Company compare 10.6×
SNY Sanofi compare 11.2×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
GILD Gilead Sciences, Inc. 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GILD